Full text is available at the source.
Abstract
Chronic activation of the PERK pathway in astrocytes may disrupt glymphatic function and is associated with Alzheimer's disease pathology.
- Dysfunction of the glymphatic system is linked to the buildup of β-amyloid and tau proteins in Alzheimer's disease.
- Activation of the PERK-α subunit pathway in astrocytes was observed in human Alzheimer's brains and two mouse models.
- Chronic PERK activation leads to decreased protein synthesis in astrocytes and mislocalization of aquaporin-4, impairing glymphatic flow.
- Restoration of aquaporin-4 localization through astrocyte-specific PERK deletion or pharmacological inhibition enhances glymphatic clearance.
- Targeting the astrocytic PERK-CK2-AQP4 pathway could provide a potential therapeutic approach for Alzheimer's disease.
Simplified